Hypercholesterolemia Treatment Patterns and Low-Density Lipoprotein Cholesterol Monitoring in Patients with a Diagnosis of Atherosclerosis in Clinical Practice

被引:8
作者
Davidson, Michael H. [1 ]
Gandhi, Sanjay K. [2 ]
Ohsfeldt, Robert L. [3 ]
Fox, Kathleen M. [4 ]
机构
[1] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA
[2] AstraZeneca Pharmaceut LP, Wilmington, DE USA
[3] Texas A&M Hlth Sci Ctr, Dept Hlth Policy & Management, College Stn, TX USA
[4] Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA
关键词
Atherosclerosis; Hypercholesterolemia; Statin; LIPID-LOWERING-THERAPY; CORONARY ATHEROSCLEROSIS; CARDIOVASCULAR-DISEASE; PREVENTION; PROGRESSION; REGRESSION;
D O I
10.1016/j.amjmed.2008.10.017
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Little is known about the lipid profiles and associated treatment patterns of patients in whom atherosclerosis is diagnosed. This investigation assessed and described the low-density lipoprotein (LDL) cholesterol levels and treatment patterns for hypercholesterolemia in patients with atherosclerosis who were treated in routine clinical practice. This retrospective database study used a random sample (1 million patients) from a national outpatient electronic medical record database (GE Medical Systems, Milwaukee, WI) and included patients with a diagnostic code for atherosclerosis (International Classification of Diseases [ICD]-9 code of 440. xx or 414. x or 437.x) between January 2004 and March 2006. Use of hypercholesterolemia medications at the time ICD codes for atherosclerosis were recorded and thereafter was documented. Patient demographics, comorbid conditions, baseline LDL cholesterol (closest value within 6 months of the diagnosis date), and follow-up LDL cholesterol (after diagnosis) were also documented. A total of 10,637 eligible patients had an ICD diagnostic code for atherosclerosis. Most patients (61.3%) were not taking any dyslipidemia medication at the time of and after atherosclerosis diagnosis. A total of 3% were prescribed therapy with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) before the time of atherosclerosis diagnosis, and 25% were prescribed a statin after diagnosis. Approximately 62% of patients with atherosclerosis did not have a baseline LDL cholesterol estimate. Of patients with LDL cholesterol recorded at diagnosis (n = 4,067), 24% had LDL cholesterol >= 130 mg/dL (1 mg/dL = 0.02586 mmol/L), 53% had LDL cholesterol >= 100 mg/dL, and 87% had LDL cholesterol > 70 mg/dL. Among patients with LDL cholesterol >= 100 mg/dL at diagnosis, 57% were not prescribed statin treatment after diagnosis. Of those with baseline and postdiagnosis LDL cholesterol values (n = 1,395), 49% had baseline LDL cholesterol >= 100 mg/dL. Among patients on statin or any other hypercholesterolemia therapy after diagnosis who had baseline and follow-up LDL cholesterol values (n = 682), 87% had baseline LDL cholesterol > 70 mg/dL and 51% had baseline LDL cholesterol >= 100 mg/dL, whereas 82% had postdiagnosis LDL cholesterol > 70 mg/dL and 43% had postdiagnosis LDL cholesterol >= 100 mg/dL. The results from this study, which was conducted in a routine clinical practice setting, indicate the opportunities and the need for better monitoring and management of lipid levels in patients with atherosclerosis. (c) 2009 Published by Elsevier Inc. The American Journal of Medicine (2009) 122, S51-S59
引用
收藏
页码:S51 / S59
页数:9
相关论文
共 19 条
[1]  
Castelli W, 1998, Value Health, V1, P105, DOI 10.1046/j.1524-4733.1998.120105.x
[2]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[3]   Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis - The METEOR trial [J].
Crouse, John R., III ;
Raichlen, Joel S. ;
Riley, Ward A. ;
Evans, Gregory W. ;
Palmer, Mike K. ;
O'Leary, Daniel H. ;
Grobbee, Diederick E. ;
Bots, Michiel L. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 297 (12) :1344-1353
[4]   Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations [J].
Davidson, MH ;
Maki, KC ;
Pearson, TA ;
Pasternak, RC ;
Deedwania, PC ;
McKenney, JM ;
Fonarow, GC ;
Maron, DJ ;
Ansell, BJ ;
Clark, LT ;
Ballantyne, CM .
AMERICAN JOURNAL OF CARDIOLOGY, 2005, 96 (04) :556-563
[5]   European guidelines on cardiovascular disease prevention in clinical practice -: Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice [J].
De Backer, G ;
Ambrosioni, E ;
Borch-Johnsen, K ;
Brotons, C ;
Cifkova, R ;
Dallongeville, J ;
Ebrahim, S ;
Faergeman, O ;
Graham, I ;
Mancia, G ;
Cats, VM ;
Orth-Gomér, K ;
Perk, J ;
Pyörälä, K ;
Rodicio, JL ;
Sans, S ;
Sansoy, V ;
Sechtem, U ;
Silber, S ;
Thomsen, T ;
Wood, D .
EUROPEAN HEART JOURNAL, 2003, 24 (17) :1601-1610
[6]  
Grundy Scott M, 2004, J Am Coll Cardiol, V44, P720, DOI 10.1016/j.jacc.2004.07.001
[7]   Five-year survival after first-ever stroke and related prognostic factors in the Perth Community Stroke Study [J].
Hankey, GJ ;
Jamrozik, K ;
Broadhurst, RJ ;
Forbes, S ;
Burvill, PW ;
Anderson, CS ;
Stewart-Wynne, EG .
STROKE, 2000, 31 (09) :2080-2086
[8]   Regression of coronary atherosclerosis by simvastatin - A serial intravascular ultrasound study [J].
Jensen, LO ;
Thayssen, P ;
Pedersen, KE ;
Stender, S ;
Haghfelt, T .
CIRCULATION, 2004, 110 (03) :265-270
[9]   Peripheral and cerebral atherothrombosis and cardiovascular events in different vascular territories: Insights from the Framingham Study [J].
Kannel W.B. ;
Wolf P.A. .
Current Atherosclerosis Reports, 2006, 8 (4) :317-323
[10]   Relation of coronary artery disease to atherosclerotic disease in the aorta, carotid, and femoral arteries evaluated by ultrasound [J].
Khoury, Z ;
Schwartz, R ;
Gottlieb, S ;
Chenzbraun, A ;
Stern, S ;
Keren, A .
AMERICAN JOURNAL OF CARDIOLOGY, 1997, 80 (11) :1429-1433